Mode
Text Size
Log in / Sign up
N/A N=42 Randomized Prevention

Performance of a Single-use Intermittent Micro-hole Zone Catheter

Urinary Incontinence · Retention, Urinary

Enrolled (actual)
42
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Number of Flow-stop Episodes — 0.17; 1.09 Flow stop episodes — p=<0.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Investigational device - intermittent catheter with a micro-hole zone (Device); Comparator device -VaPro intermittent catheter (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
Male
Sponsor
Coloplast A/S
Primary completion
Nov 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Flow-stop Episodes
0.17; 1.09 0.05
PRIMARY
Residual Urine at 1st Flow-stop
5.10; 39.40 0.05
PRIMARY
Number of Flow-stop Episodes
0.17; 1.09 0.05

Summary

The goal of this randomized, controlled crossover study was to assess the performance of a new micro-hole zone catheter compared to a conventional 2-eyelet catheter in 42 male intermittent catheter users. The main objective of this study was to demonstrate superiority of the micro-hole zone catheter in terms of number of flow-stop episodes and residual volume at first flow-stop, with the catheterization performed by a health care professional in a hospital setting compared to a conventional two-eyelet catheter.

Eligibility Criteria

Inclusion Criteria

  • Is Male
  • Is at least 18 years of age and has full legal capacity
  • Has given written informed consent
  • Has signed letter of authority (only DK)
  • Has used clean intermittent catheterisation CH12 or CH14 for at least one month
  • Use intermittent catheterisation as the primary bladder emptying method
  • Is able (assessed by investigator) and willing to follow study procedures

Exclusion Criteria

  • Is participating in any other clinical study during this investigation
  • Has previous participated in this study
  • Has symptoms of urinary tract infection as judged by the investigator 4 Is an individual with history, suspected or showing signs of producing urine with excessive amount of mucus or large/clustered sediments or debris
  • Has any known allergies towards ingredients in the investigational device
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05485922). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search